Journal

International Journal of Surgery

Papers (50)

Appraisal the significance of completion hysterectomy after definitive concurrent chemoradiotherapy for patients with locally advanced cervical adenocarcinoma: the ATTRACT study

Objective: To appraise whether the completion hysterectomy after concurrent chemoradiotherapy (CCRT) would improve the survival outcomes for patients with locally advanced cervical adenocarcinoma (LACA). Methods: This study was conducted based on a large cohort including more than 200 LACA patients from Peking Union Medical College Hospital. The included patients were divided into the CCRT alone and CCRT + surgery groups, where overall survival (OS), progression-free survival (PFS), loco-regional-free survival (LRFS), and distant metastasis-free survival (DMFS) were compared between the two groups before and after propensity scoring matching (PSM). Cox regression analysis was performed in the CCRT alone group to identify the risk factors impairing the survival probability. The survival outcomes were further compared between the CCRT alone and the CCRT + surgery group in different risk subgroups identified from Cox regression analysis. Results: CCRT + surgery was observed to outperform CCRT alone in OS, PFS, LRFS, and DMFS before PSM (all P < 0.05), while the benefit of surgery could not be maintained after PSM except for DMFS (3-year DMFS: 76.8 vs. 60.2%, P = 0.035). Uterus involvement (UI) was identified as the only risk factor for the CCRT alone group. Surgery was found to increase the survival probability for patients with UI (all P < 0.05), while it did not bring additional survival benefit for patients without UI (all P > 0.05). In the CCRT + surgery group, patients with pathological residual disease (RD) ≥ 1/2 myometrial infiltration (MI) had significantly decreased survival compared to patients with RD<1/2MI or patients without RD (all P < 0.05). Furthermore, postoperative chemotherapy didn’t improve survival outcomes in patients with RD<1/2MI, while it seemed to bring additional benefit for patients with RD≥1/2MI in terms of PFS with marginal significance ( P = 0.055). Conclusion: Completion hysterectomy after CCRT could increase DMFS for LACA patients, while not every LACA patient would retain OS benefit from surgery, except for those with positive UI. Survival differences existed in different degrees of RD among patients receiving post-radiation surgery and postoperative chemotherapy, demonstrating a trend toward PFS benefit for patients with RD≥1/2MI.

Radiomics-based prognostic model for progesterone resistance in endometrial cancer: insights into extracellular matrix and type III collagen

Background: Progesterone resistance in fertility-preserving patients with endometrial cancer (EC) remains a significant challenge, and radiomics has not yet been used to predict progestin therapy in these cases. Results: In this study, we constructed a radiomics model to predict progesterone resistant for fertility preservation patients. Distribution of clinical features have significant differences in the high and low risk of progesterone-resistant subgroups, which we call predicting-sensitive (PS) versus predicting-resistant (PR) subgroups. The radiomics model achieved high predictive accuracy with an area under the receiver operating characteristic curve (AUC) of 0.841 in the training cohort. We further validate this model in the validation and whole cohorts. As a result, the AUCs were 0.873 and 0.852, respectively. The identified key biological pathways include cellular response to external stimulus, collagen metabolic processes, and extracellular matrix (ECM) remodeling. PS was strongly linked to higher type III collagen content and changes in ECM stiffness, which were reflected in altered tumor microenvironment dynamics. Finally, we confirmed that the PR subgroup exhibited increased cellular stiffness by microfluidic device. Exogenous supplementation of COL III enhanced the sensitivity of EC cells to progesterone and reduced cell stiffness. Conclusion: Our radiomics model provides a promising, noninvasive tool for predicting progesterone resistance in EC. This approach paves the way for personalized therapeutic strategies for fertility-preserving patients.

Detection of metastatic lymph node and sentinel lymph node mapping ​using mannose receptor targeting in in vivo mouse footpad tumor models and rabbit uterine cancer models

Background: This study aimed to evaluate the effectiveness of neo-mannosyl human serum albumin-indocyanine green (MSA-ICG) for detecting metastatic lymph node (LN) and mapping sentinel lymph node (SLN) using mouse footpad uterine tumor models. Additionally, the authors assessed the feasibility of MSA-ICG in SLN mapping in rabbit uterine cancer models. Materials and methods: The authors compared the LN targeting ability of MSA-ICG with ICG. Six mouse footpad tumor models and two normal mice were each assigned to MSA-ICG and ICG, respectively. After the assigned tracers were injected, fluorescence images were taken, and the authors compared the signal-to-background ratio (SBR) of the tracers. A SLN biopsy was performed to confirm LN metastasis status and CD206 expression level. Finally, an intraoperative SLN biopsy was performed in rabbit uterine cancer models using MSA-ICG. Results: The authors detected 14 groin LNs out of 16 in the MSA-ICG and ICG groups. The SBR of the MSA-ICG group was significantly higher than that of the ICG group. The metastatic LN subgroup of MSA-ICG showed a significantly higher SBR than that of ICG. CD206 was expressed at a high level in metastatic LN, and the signal intensity difference increased as the CD206 expression level increased. SLN mapping was successfully performed in two of the three rabbit uterine cancer models. Conclusions: MSA-ICG was able to distinguish metastatic LN for an extended period due to its specific tumor-associated macrophage-targeting property. Therefore, it may be a more distinguishable tracer for identifying metastatic LNs and SLNs during uterine cancer surgery. Further research is needed to confirm these results.

Causes of death after surgery among cancer patients: a population-based cohort study

Introduction: Recent advancements in surgical techniques and perioperative care have improved cancer survival rates, yet post-operative comorbidity and mortality remain a critical concern. Despite progress in cancer control, systematic analyses of long-term mortality trends and competing risks in surgery-intervened cancer populations are lacking. This study aimed to quantify temporal patterns of post-operative mortality causes across 21 solid cancers and identify dominant non-cancer risk factors to inform survivorship care strategies. Methods: This retrospective, population-based cohort study analyzed data from 3 424 671 patients (including 2 371 058 surgical cases) diagnosed with 21 solid cancers between 1992 and 2021, sourced from the Surveillance, Epidemiology, and End Results database. Competing risk models were applied to assess cumulative mortality rates from index-cancer, non-index-cancer, and non-cancer causes, with stratification by cancer type. Surgical interventions were evaluated across short-term (30-day) and long-term follow-up periods, with primary outcomes focused on mortality attribution and secondary outcomes on temporal dominance shifts. Results: In this population-based retrospective cohort study of 3 424 671 patients with 21 solid cancers (1992–2021), non-cancer deaths surpassed index-cancer mortality in 14 malignancies (e.g., prostate, breast, colorectal), accounting for 48.7% of post-surgical deaths, with cardiovascular diseases and infections as primary contributors. By the 2020s, non-cancer causes emerged as the leading mortality driver in these cancers. However, index-cancer mortality remained predominant in pancreatic, ovarian, and brain tumors, highlighting the persistent therapeutic gaps. Surgical resection significantly altered mortality profiles for cancer population, with a 95.7% increase in non-cancer mortality for lung cancer and an 87.3% increase for pancreatic cancer ( P < 0.001), underscoring the critical need for enhanced post-operative comorbidity management. While 1-month post-surgical mortality improved over three decades for most solid cancers, disparities persisted in brain, biliary tract, and colorectal cancers. These findings advocate for multidisciplinary strategies prioritizing non-cancer comorbidities, particularly cardiovascular and infectious risks, to optimize long-term survival in cancer survivors. Conclusion: This study highlights a paradigm shift in post-operative mortality, with no-cancer cause of deaths now surpassing cancer-related deaths in most solid tumors. These findings underscore the urgency of integrating multidisciplinary care targeting cardiovascular health and infection prevention into survivorship programs.

Distinct roles of HMOX1 on tumor epithelium and macrophage for regulation of immune microenvironment in ovarian cancer

Background: Ferroptosis has been implicated in the regulation of the tumor immune environment; however, its precise effect on immune checkpoint inhibitors remains contradictory. Objective: To elucidate the “double-edged sword effect” of a key ferroptosis-related factor in regulating the immune microenvironment. Methods: This study utilized single-cell RNA sequencing (scRNA-seq) analysis to characterize the tumor microenvironment in ovarian cancer samples from immunotherapy cohorts. Following quality control and variable gene screening, data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), GENE EXPRESSION OMNIBUS (GEO), bulk, and spatial transcriptome databases were analyzed. The AddModuleScore_UCell function was employed for gene set scoring by evaluating the expression patterns of specific gene features in single-cell datasets, which were found to correlate with interactions between tumor cells and stromal cells, recognized as key contributors in the immunosuppressive milieu. Immunohistochemistry, western blot, and multiplex immunohistochemistry (mIHC) analyses were employed to explore the HMOX1/TGF-β1/PI3K/AKT/NF-κB(p65) signaling pathways. In vitro findings were further validated in a mouse model. The correlation between risk factors and progression-free survival (PFS) was analyzed using Cox regression and Kaplan–Meier methods. Results: We demonstrated decreased expression of the ferroptosis-activating gene HMOX1 in ovarian cancer epithelial cells, while being upregulated in macrophages. Ovarian cancer (OV) epithelial cells with HMOX1 inhibition could secrete TGF-β1 to activate three macrophage subtypes: SPP1 + , FOLR2 + , and C1QC + via the PI3K/AKT/NF-κB (p65) pathway. The up-regulation of HMOX1 in macrophages also activated these three macrophage subtypes via the NF-κB pathway. Both pathways simultaneously inhibited Cytotoxic T Lymphocyte (CTL) activation and contributed to the immunosuppressive microenvironment of ovarian cancer, as demonstrated in both in vitro and in vivo models. Targeting HMOX1 alone, whether through activation or inhibition, was only effective in modulating a single pathway while simultaneously inducing negative feedback on the opposing pathway, demonstrating the “double-edged sword effect” of HMOX1 in regulating the immune microenvironment. Conclusion: Overall, we proposed and validated two strategies targeting HMOX1 to improve the efficacy of PD-1 inhibitors, and confirmed that HMOX1, TGF-β1, SPP1, FOLR2, and C1QC could be used to construct models predicting the efficacy of immune checkpoint inhibitors.

Universal screening for Lynch syndrome and molecular classification of patients with endometrial cancer

Objective: Lynch syndrome (LS) is a cancer susceptibility syndrome characterized by a high risk table of multiple cancer types, most commonly endometrial cancer (EC). Currently, universal tumor screening to identify LS in women with EC remains uncommon. This study aimed to determine the incidence of LS and its molecular landscape by conducting a retrospective analysis of a cohort of patients with EC in China. Methods: A total of 220 patients with EC were identified from the Hospital between March 2022 and May 2025. Germline variants in LS-associated genes ( MLH1, PMS2, MSH2, MSH6 , and EPCAM ) and molecular subtypes [ POLE, TP53 genes, and microsatellite instability (MSI)] were analyzed using next-generation sequencing (NGS). Mismatch repair (MMR) proteins were screened by immunohistochemistry (IHC). Tumors with loss of MLH1 or MLH1/PMS2 protein expression were tested for MLH1 promoter methylation. Results: Of the 220 cases, 16 (7.3%) had a pathogenic germline variant in MMR genes, with the majority identified in MSH6 ( n = 7), followed by MLH1 ( n = 3), PMS2 ( n = 3), and MSH2 ( n = 3). A total of 22 EC tumors (10.0%) carried a variant of uncertain significance in the LS-associated genes. Our results revealed that the percentages of the different molecular subtypes were POLE-mutated (POLEmut; 10.9%), mismatch repair deficient (MMRd; 25.5%), p53 abnormal (p53abn; 8.6%), and no specific molecular profile (NSMP; 55.0%). Ten “multiple-classifier” tumors (4.5% of the total cases) were identified. These included five MMRd-p53abn, four POLEmut-p53abn, and one POLE-MMRd. Conclusion: This study confirms the effectiveness of NGS in identifying germline variants within a Chinese cohort of patients with EC, revealing an LS prevalence of 7.3%. Relying solely on MMR-IHC or MSI testing could lead to missed diagnoses of LS. Our findings contribute to a better understanding of the mutational landscape and prevalence of LS.

Fatty acid-binding proteins in cancers

Fatty acid-binding proteins (FABPs) are intracellular lipid chaperones with molecular weights of approximately 14-15 kDa. By binding and transporting fatty acids and lipid-related molecules, FABPs precisely regulate metabolic pathways, signal transduction, and gene expression, playing a central role in cancer initiation and progression. The 11 identified subtypes (FABP1-FABP12; FABP11 is identical to FABP3) exhibit tissue-specific expression and influence tumor progression through metabolic reprogramming, immune microenvironment modulation, and therapy resistance. Metabolically, FABPs enhance fatty acid uptake, β-oxidation, and synthesis, meeting the high proliferative demands of tumors. In immune regulation, FABP4 + macrophages secrete IL-6 to suppress T cell activity, while FABP6 downregulates MHC-I molecule expression to reduce CD8 + T cell infiltration, fostering an immunosuppressive microenvironment. Regarding therapy resistance, FABP4 enhances mitochondrial β-oxidation to reduce apoptosis in ovarian cancer, and FABP5 promotes chemoresistance in HCC via the HIF-1α pathway. Functional heterogeneity exists among subtypes: FABP7 drives glioblastoma stem cell migration via RXRα signaling, while FABP5 exhibits context-dependent roles, promoting HCC progression but suppressing colorectal cancer (CRC) through mTOR-mediated autophagy. Clinically, FABPs serve as diagnostic biomarkers and therapeutic targets. However, challenges such as insufficient target specificity, cross-cancer heterogeneity, and normal tissue toxicity remain. Future studies should integrate multi-omics and single-cell technologies to elucidate cell-specific mechanisms and develop precise combination therapies for clinical translation.

Application of hysteroscopic morphology in endometrial cancer diagnosis and fertility preservation: scientific insights and clinical artistry

Endometrial cancer (EC) is one of the most common gynecologic malignancies, with rising incidence in younger women. Given the favorable prognosis of early-stage disease, accurate diagnosis and effective fertility-preserving strategies are increasingly important. Hysteroscopy, enabling direct visualization of intrauterine lesions, plays a key role in both diagnosis and conservative management. This review summarizes current evidence on hysteroscopic morphological features of EC and their clinical significance. Classification based on surface architecture and atypical vascular patterns − such as glomerular and cerebroid types − provides early clues to tumor grade and prognosis. Tumor spread patterns (focal vs. diffuse) correlate with staging and survival outcomes, while hysteroscopic scoring systems enhance diagnostic precision. In fertility-preserving treatment, combining hysteroscopic resection with progestin therapy significantly improves complete remission rates and shortens treatment duration. Assisted reproductive technology further increases pregnancy and live birth outcomes post-remission. Molecular classification enables more tailored fertility-sparing strategies. Advances in imaging − such as narrow-band imaging and 5-aminolevulinic acid photodynamic diagnosis − enhance lesion detection by improving vascular visualization. Artificial intelligence–based hysteroscopic image analysis supports consistent lesion classification and fertility outcome prediction. Although concerns remain regarding retrograde dissemination, evidence affirms the safety and efficacy of hysteroscopy when properly performed. Hysteroscopic morphology, integrated with molecular profiling and advanced imaging technologies, represents a valuable and minimally invasive approach to personalized diagnosis and fertility preservation in EC.

Unraveling the prognostic puzzle: an in-depth exploration of lymph node metrics in surgically treated FIGO stage IB-IIA cervical cancer – A retrospective cohort study focused on the number of positive lymph nodes and the lymph node ratio

Background: Lymph node (LN) metastasis constitutes a major adverse prognostic factor in surgically treated cervical cancer (CC) patients. Leveraging the Surveillance, Epidemiology, and End Results database, this study aimed to evaluate the prognostic value of the number of positive LN metastases (nLNM) and LN ratio (LNR) in patients with stage IB-IIA CC who underwent surgical treatment. Methods: A retrospective analysis was conducted on patients with histopathologically confirmed CC between 2010 and 2021, with overall survival (OS) as the primary endpoint. nLNM stratification was performed using X-title software, followed by Kaplan–Meier (K-M) analysis. For LNR, restricted cubic spline (RCS) analysis identified inflection points between the number of examined regional LNs and OS. Subsequently, X-title software and K-M analysis independently compared OS between the negative and positive LN(s) groups. Results: A total of 100 097 LNs from 5911 CC patients were analyzed. Among these, 856 (14.48%) patients had positive LNs. The presence of positive LNs was associated with a significantly lower 10-year OS rate compared to those with negative LNs (69.0% vs. 86.7%, P < 0.001). The nLNM stratification, generated using X-title software and K-M analysis, exhibited the highest discriminatory power with categories of negative vs. 1–3 + vs. ≥4+ LNs metastasis (all P < 0.001). RCS analysis revealed a nadir at 15 examined LNs and indicated excluding patients with fewer than 8 LNs examined during surgery. No OS difference was observed between patients with 9–15 LNs and those with ≥16 LNs examined when LNR = 0 ( P = 0.365). However, an LNR ≥0.210 was associated with significantly poorer OS ( P < 0.01). Conclusion: Extensive pelvic lymphadenectomy provided no survival benefit for patients with ≥16 examined, pathologically negative LNs compared to those with 9–15 LNs examined. Both nLNM ≥4+ and LNR ≥0.210 were identified as significant prognostic factors, offering valuable insights for clinical decision-making.

Surgical approach, preoperative LEEP/conization and patterns of recurrence and death in low-risk cervical cancer – exploratory analysis from the CCTG CX.5/SHAPE trial

Background: SHAPE demonstrated that simple hysterectomy was not inferior to radical hysterectomy in patients with low-risk cervical cancer. To further understand the role of preoperative LEEP/conization, clear LEEP/conization margins and surgical approach, analyses were performed regarding patterns of recurrence and death. Patients and methods: Outcomes (pelvic recurrence, extrapelvic recurrence and cervical cancer-related death) by surgical approach (minimally invasive surgery [MIS] vs. open), LEEP/conization (yes vs. no, involved vs. negative margins) and residual disease in the hysterectomy specimen (yes vs. no) are described with 3-year outcome rate estimated by Kaplan–Meier method and compared by Cox models. Results: With a median follow-up of 4.5 years, 25 (3.7%) recurrences (pelvic or extrapelvic) were observed from 680 patients who underwent simple (338) or radical (342) hysterectomy. At surgeons’ discretion, MIS was performed in 524 (77%) and open surgery in 156 (23%). Overall, 19 recurrences occurred following MIS (3.6%) and 6 following open surgery (3.8%). Among 174 patients with clear margins after LEEP/conization, 2 (1.4%) developed pelvic recurrences after MIS and none after open surgery. Among the entire cohort, 9 patients had extrapelvic recurrence, 7/524 (1.3%) following MIS and 2/156 (1.3%) following open surgery. However, no extrapelvic recurrence occurred after either MIS or open surgery among patients who had pre-hysterectomy LEEP/conization with clear margins. With regards to cervical cancer-related deaths, all occurred after MIS (5/524, 0.95%) and none after open surgery or after previous LEEP/conization with clear margins. Conclusions: Similar rates of recurrence and death were observed between patients who underwent MIS and open surgery within the SHAPE cohort. No extrapelvic recurrences and death occurred in patients with clear margins following prior LEEP/conization, regardless of surgical approach. The concept of pre-hysterectomy LEEP/conization might help to triage the most effective surgical strategy in terms of surgical approach and radicality in low-risk cervical cancer patients to ensure safe outcomes.

Single-cell and spatial transcriptome analysis revealed cellular heterogeneity of glycosyltransferases in cervical cancer, and identified GALNT3-negative epithelial cells as a protective factor: a retrospective cohort study based on public database

Introduction: Cervical cancer (CC) is a common and deadly malignancy among women worldwide, characterized by high mortality and poor prognosis. Glycosyltransferases (GTs) are enzymes that catalyze glycosyl transfer reactions and play significant roles in cancer development and progression. However, their role in cervical cancer remains unclear. Methods: This study combined single-cell RNA sequencing (scRNA-seq) data and spatial transcriptomics (stRNA-seq) to explore the role of GTs in cervical cancer. We utilized comprehensive scoring algorithms to evaluate GT expression, conducted cell communication analysis, and identified differentially expressed GT-related genes in tumor-associated epithelial cells. Functional assays were performed to assess the impact of GALNT3 expression on cervical cancer cell proliferation and invasiveness. Results: Our analysis revealed that GT-related genes are highly enriched in cervical cancer epithelial cells. We identified 11 differentially expressed GT-related genes, including GALNT3, which showed distinct characteristics in epithelial cells. GALNT3-negative epithelial cells were found to be a protective factor for cervical cancer patients, showing a significant negative correlation with tumor-associated macrophages and myeloid-derived suppressor cells. Knockdown or overexpression of GALNT3 significantly affected cell proliferation and invasiveness in C-33A and Caski cell lines. Conclusion: This study highlights the critical role of GTs, particularly GALNT3, in the progression and prognosis of cervical cancer. GALNT3-negative epithelial cell infiltration could be a favorable factor for cervical cancer prognosis, providing new insights for therapeutic strategies targeting GTs in cervical cancer.

Laparoscopic radical hysterectomy with Karez technique for stage IB3 and IIA2 cervical cancer: a multicenter retrospective cohort study

Background: Laparoscopic radical hysterectomy with Karez technique (LRH-Karez) is a practical method which is based on special space anatomy. This study investigates the efficacy and safety of LRH-Karez against traditional surgical methods including abdominal radical hysterectomy (ARH) and conventional minimally invasive surgery (MIS). Methods: A multicenter retrospective cohort study was conducted, involving 413 eligible patients diagnosed with 2018 FIGO stage IB3 and IIA2 cervical cancer treated from January 2012 to January 2022. Among these, 66 patients underwent LRH-Karez, 56 patients underwent conventional laparoscopic or robotic surgery (Conventional MIS) and 291 patients received ARH. Patient data were obtained from three tertiary hospitals in China. Surgical outcomes, pathological results, and follow-up data were analyzed using SPSS and R statistical software. Kaplan–Meier survival analysis was performed alongside univariate and multivariate Cox regression analyses. Results: LRH-Karez has less intraoperative blood loss but longer operative time. The five-year progression-free survival (PFS) rates were 85% for LRH-Karez, significantly higher than the 53.6% from conventional MIS (P = 0.002) and comparable to ARH (78.3%, P = 0.898). In terms of overall survival, the five-year overall survival (OS) rate for the LRH-Karez group was 92.2%, compared to 51.9% for the conventional MIS group and 78.3% for the ARH group. Patients who underwent conventional MIS had significantly lower OS compared to those in the LRH-Karez group (P < 0.001). The log-rank test indicated no significant difference in OS between the LRH-Karez group and the ARH group (P = 0.218). However, the Gehan-Breslow-Wilcoxon test revealed a significant difference between the two groups during the early follow-up period (P = 0.047). Conclusions: The LRH-Karez technique has demonstrated superior intraoperative safety and survival prognosis compared to conventional MIS in patients with locally advanced cervical cancer (FIGO stages IB3 and IIA2), with its long-term survival outcomes comparable to ARH. This practical technique, based on refined understanding of surgical space anatomy, may represent a valuable minimally invasive surgical option that warrants further exploration.

The prognosis of patients with locally advanced cervical cancer undergoing surgical versus non-surgical treatment: a retrospective cohort study based on SEER database and a single-center data

The aim of this study was to investigate the impact of surgical treatment on the survival prognosis of patients with locally advanced cervical cancer (LACC) and to identify factors that may influence the efficacy of surgery. Data from the SEER database (2000–2020) and a hospital (2013–2023) were collected for this investigation. Utilizing multivariable Cox regression analysis, Kaplan–Meier survival analysis, and log-rank tests, we assessed the effects of surgical intervention on overall survival (OS) and disease-specific survival (DSS) in LACC patients. Our results revealed that in the SEER database, the surgical group exhibited significantly better OS and DSS compared to the non-surgical group. Particularly noteworthy was the significantly higher survival rate in the surgical group for patients with tumor diameters less than 6 cm. Furthermore, both OS and DSS were improved in the surgical group regardless of whether the cancer was squamous cell carcinoma or adenocarcinoma. Additionally, patients who underwent surgery combined with radiotherapy had notably better OS and DSS compared to those who received chemoradiotherapy alone. Similarly, our hospital data showed that the surgical group demonstrated significantly better OS than the non-surgical group, especially for patients with tumors smaller than 6 cm in diameter. These findings suggest that surgery combined with radiotherapy may offer more favorable outcomes than chemoradiotherapy alone, particularly for LACC patients with smaller tumors.

Utilizing explainable machine learning for progression-free survival prediction in high-grade serous ovarian cancer: insights from a prospective cohort study

Background: High-grade serous ovarian cancer (HGSOC) remains one of the most challenging gynecological malignancies, with over 70% of ovarian cancer patients ultimately experiencing disease progression. The current prognostic tools for progression-free survival (PFS) in HGSOC patients have limitations. This study aims to develop an explainable machine learning (ML) model for predicting PFS in HGSOC patients. Methods: Nine ML algorithms for PFS prediction were developed using a prospective cohort of 310 HGSOC patients consecutively enrolled from a large Chinese tertiary hospital between January 2017 and December 2020. The optimal model was internally validated using the 1000 bootstrap method. The SHapley Additive exPlanations (SHAP) method was employed to interpret the model in terms of feature importance and feature effects. The final model, constructed with the optimal feature subset, was deployed as an interactive web-based Shiny app. Results: The random survival forest (RSF) model demonstrated superior predictive performance compared to other ML models, the RFS model constructed with an optimal feature subset in the optimal imputed dataset achieved a superior 1000 bootstrap C-index of 0.755 (95% CI: 0.750–0.780) and a Brier score of 0.183 (95% CI: 0.175–0.190). SHAP analysis identified tumor residual, HE4, FIGO stage, T stage, CA125, age, ascites volume, platelet counts, and BMI as the top nine contributing factors. It also revealed potential nonlinear relationships and important thresholds between HE4, CA125, age, ascites volume, platelet counts, the body mass index, and PFS risk. Additionally, interaction effects were found between tumor residual and age, HE4, and CA125. Finally, an interactive web-based Shiny app for the model was developed and accessible at https://rsfmodels.shinyapps.io/ocRSF/. Conclusion: An explainable ML model for PFS prediction in HGSOC patients was developed with superior results. The publicly accessible web tool based on the optimized model facilitates its utility in clinical settings, potentially improving individualized patient management and treatment decision-making in HGSOC.

Polyphyllin H inhibits malignant progression of ovarian cancer in patient-derived xenograft mouse models by regulating CGN/RhoA/Rock2 axis: an experimental research

Background: Discovering new and effective drugs is a top priority for treating ovarian cancer, a gynecological tumor with a high mortality rate. As a major active ingredient isolated from Paris polyphylla , Polyphyllin H exhibits antitumor effect. However, its efficacy in ovarian cancer remains unknown. This study is designed to elucidate the antitumor activity and underlying mechanism of polyphyllin H in ovarian cancer. Materials and methods: Polyphyllin H was selected from 20 traditional Chinese medicine monomers based on its high anti-proliferative activity in CCK-8 assays performed on human ovarian cancer cell lines. The effects of polyphyllin H at different concentrations on cultured ovarian cancer cells were evaluated. Polyphyllin H was administered intragastrically to the cell line-derived xenograft (CDX) mice with ovarian cancer and the tumor inhibitory effects were assessed, and the potential anti-ovarian cancer mechanisms were predicted through protein sequencing. Subsequently, the therapeutic potential was further verified in patient-derived xenograft (PDX) mouse model. Results: The in vitro experiments demonstrated that polyphyllin H potently inhibited the proliferation, invasion, and migration of ovarian cancer cells while promoting cellular apoptosis. In vivo studies further confirmed that polyphyllin H significantly suppressed ovarian tumor growth, without inducing hepatic, renal and hematopoietic dysfunction, intestinal flora disturbance and major visceral histopathological change. Mechanistically, polyphyllin H upregulated cingulin (CGN) expression, blocking the RhoA/Rock2 signaling pathway to inhibit ovarian cancer malignant progression. Notably, polyphyllin H exerted promising antitumor efficacy in ovarian cancer PDX model, particularly demonstrating superior therapeutic effects against Her2-positive ovarian cancer. Conclusion: This study demonstrates that polyphyllin H inhibits the malignant progression of ovarian cancer via the CGN/RhoA/Rock2 pathway, without notable toxic and side effects. It provides a novel candidate drug for ovarian cancer therapy. Notably, the efficacy of polyphyllin H in ovarian cancer PDX models indicates its translational potential for clinical application.

Impact of regional lymph node surgery and lymph node status on survival of small cell cervical cancer patients undergoing primary site surgery

Objective: Small cell carcinoma of the cervix (SCCC) is a rare and highly aggressive malignancy with limited evidence to guide surgical management. We therefore aimed to evaluate the prognostic value of regional lymph node (LN) surgery and LN status in patients with SCCC undergoing primary tumor resection. Methods: In this retrospective cohort study, data were obtained from the Surveillance, Epidemiology, and End Results database (January 1, 2000 to December 31, 2021). A total of 204 patients with histologically confirmed SCCC who underwent primary tumor resection were included and classified according to receipt of regional LN surgery. An independent validation cohort with 121 patients was retrospectively identified from our center (January 1, 2013 to December 31, 2020). Kaplan–Meier curves, multivariable Cox proportional hazards models, and stratified subgroup analyses were performed. Results: Of the 204 included patients, 141 (69.1%) underwent regional LN surgery and 63 (30.9%) did not. Baseline demographic and clinicopathologic characteristics were similar between groups. In patients with International Federation of Gynecology and Obstetrics (FIGO) stage I–IVA disease, regional LN surgery was not associated with improved cancer-specific survival (CSS) (adjusted hazard ratio [HR], 1.16; 95% confidence interval [CI], 0.52–2.56; P = 0.722), and LN-negative status was not prognostic. Among those with stage IVB disease, LN surgery was associated with significantly better survival (adjusted HR, 0.24; 95% CI, 0.08–0.77; P = 0.016). In the independent validation cohort, LN status was not significantly associated with recurrence-free survival (HR, 1.163; 95% CI, 0.37–3.61; P = 0.794) or CSS (HR, 1.39; 95% CI, 0.44–4.40; P = 0.575). Conclusion: Regional LN surgery did not improve survival among patients with FIGO stage I–IVA SCCC, and LN status alone was not an independent prognostic indicator. However, LN surgery may confer potential benefit in FIGO stage IVB disease. These findings suggest that LN dissection should be considered carefully and highlight the need for individualized surgical decision-making and prospective validation.

Simplifying surgical criteria for early-stage cervical cancer: prognostic equivalence of total vs. radical hysterectomy in a retrospective SEER cohort analysis

Background: The prognostic equivalence of total hysterectomy (TH) versus radical hysterectomy (RH) in early-stage cervical cancer (IA2-IB1) with tumor size ≤2 cm remains controversial, particularly regarding the necessity of lymphovascular space invasion (LVSI) assessment. This study evaluates survival outcomes under simplified criteria omitting LVSI and depth of invasion evaluation. Materials and methods: This retrospective cohort study analyzed 3002 FIGO IA2-IB1 cervical cancer patients (tumors ≤2 cm) from the SEER database (2004–2019). Inclusion criteria are histologically confirmed adenocarcinoma, adenosquamous carcinoma, or squamous cell carcinoma; TH/RH with lymphadenectomy/sentinel node biopsy. Outcomes included overall survival (OS) and disease-specific survival (DSS), analyzed via Kaplan–Meier, Cox regression, and propensity score matching (PSM). Results: Median follow-up was 73 months. No significant differences were observed in OS (92.3% vs. 92.3%, P = 0.74) and DSS (96.4% vs. 96.6%, P = 0.89) outcomes between RH and TH cohorts, consistent across FIGO stages and adjuvant therapy-without patients. Multivariable analysis confirmed age >49 years (HR = 2.50, 95% CI = 1.91–3.28, P < 0.01), marital status of separated/divorced/widowed (HR = 1.66, 95% CI = 1.20–2.28, P < 0.01), and tumor size 11–20 mm (HR = 1.61, 95% CI = 1.18–2.19, P < 0.01) as independent risk factors in OS. While surgical approach still showed no prognostic significance both in OS (HR = 1.04, 95% CI = 0.79–1.37, P = 0.77) and DSS (HR = 1.01, 95% CI = 0.67–1.53, P = 0.96). Post-PSM analysis (n = 2,715) confirmed survival equivalence (P > 0.05). However, in IB1 adenosquamous/adenocarcinoma patients aged >49 years with tumors 11–20 mm, RH achieved superior DSS (P = 0.01), though OS differences were nonsignificant (P = 0.085). Squamous carcinoma outcomes remained equivalent regardless of surgery (P = 0.43). Conclusion: TH achieves survival outcomes comparable to RH in most early-stage cervical cancer patients with tumors ≤2 cm, supporting its application in low-risk populations. However, RH remains preferred for stage IB1 patients with adenocarcinoma or adenosquamous carcinoma aged >49 years and tumors measuring 11–20 mm. Simplified criteria omitting LVSI and stromal depth assessment may enhance accessibility in resource-limited settings without compromising safety.

Treatment patterns and prognosis of patients with clear cell adenocarcinoma of the cervix: a population-based cohort study

Objectives: To describe treatment patterns and prognoses for clear cell adenocarcinoma of the cervix (CCAC), a poorly understood rare tumor. Methods: A retrospective case–control study was conducted using the Surveillance, Epidemiology, and End Results (SEER) database, focusing on females diagnosed with CCAC between 2000 and 2019. Kaplan–Meier analysis, propensity score matching, Cox regression analysis, and subgroup analysis were used to assess treatment outcomes and risk factors. Results: Of the 52 153 patients with cervical cancer in the SEER database, 528 had CCAC. Overall survival (OS) was worse for patients with early-stage and locally advanced CCAC disease, although no differences in survival were observed for patients with stage IVB disease compared to those with other histologies. In our investigation into treatment patterns, we have discovered that surgical treatment was the preferred choice for the majority of patients with locally advanced CCAC (58.5%). Further, Kaplan–Meier analysis revealed that surgery improved OS in CCAC patients (65.6 vs. 25.3%, P =0.000), with similar results in locally advanced-stage patients (57.9 vs. 26.7%, P =0.000). Moreover, multivariate Cox regression analysis revealed that surgery was significantly associated with a more favorable prognosis in CCAC patients with locally advanced disease (HR 0.299, 95% CI: 0.153–0.585, P =0.000). Consistent findings were observed following propensity score matching (HR 0.283, 95% CI: 0.106–0.751, P =0.011). According to the subgroup analyses, surgical intervention continued to show a beneficial effect on CCAC patients with locally advanced disease (HR=0.31, 95% CI: 0.21–0.46, P <0.001). In particular, we also found that compared to patients who received primary radiotherapy (RT), those who underwent radical surgery exhibited a significantly prolonged OS in locally advanced CCAC patients. Furthermore, multivariate Cox regression analysis revealed that surgery was associated with better outcomes in patients with stage IB3-IIA2 and locally resectable stage IIIC patients (HR 0.207, 95% CI=0.043–0.991, P =0.049). However, this trend was not observed for patients with stage IIB-IVA (except locally resectable stage IIIC) CCAC. Conclusions: Surgery should be considered the preferred treatment option for patients with locally advanced CCAC at stage IB3-IIA2 and locally resectable stage IIIC.

Effect of intraoperative low-dose esketamine on postoperative quality of recovery in patients undergoing laparotomy for gynecologic malignancy: a randomized controlled trial

Background: Gynecologic malignancy surgery with long midline incision and extensive surgical field often causes severe pain. We aimed to evaluate the benefit of low-dose esketamine on postoperative recovery after gynecologic malignancy laparotomy. Materials and Methods: In total, 140 female patients scheduled for elective gynecologic malignancy laparotomy were randomly assigned to the esketamine group ( n = 70) or control group ( n = 70). Patients in the esketamine group received an intraoperative infusion of 0.25 mg/kg/h esketamine while those in the control group received an equivalent volume of saline. Both groups received a standard multimodal analgesic regimen that consisted of transversus abdominis plane block, acetaminophen, nonsteroidal anti-inflammatory drugs, and patient-controlled morphine. The primary outcome was the Quality of Recovery-40 (QoR-40) score at 48 hours postoperatively. Secondary outcomes included morphine consumption, pain scores, adverse effects, time to post-anesthesia care unit (PACU) discharge, postoperative depressive symptom on postoperative day 7, quality of life, and chronic pain at 3 months after surgery. Results: The median QoR-40 score at 48 hours was 179 (164–190) in the esketamine group, which was not significantly different from 178.5 (163–186) in the control group (median difference, 1; 95% CI, −4 to 7; P = 0.643). Secondary outcomes were comparable between the two groups. Patients in the esketamine group had more over-sedation (20/69 [29.0%] vs. 8/70 [11.4%]; absolute risk difference (ARD), 17.6% [95% CI, 4.2–30.4%]; P = 0.010), and delayed discharge from PACU (19/69 [27.5%] vs. 4/70 [5.7%]; ARD, 21.8% [95% CI, 9.6–33.8%]; P = 0.001) compared to the control group. Conclusions: Intraoperative low-dose esketamine failed to further improve the QoR-40 score after gynecologic malignancy laparotomy when used as part of a multimodal analgesic regimen. Further research is needed to explore the optimal dosage and indications of esketamine in this patient population.

Unravelling the molecular landscape of endometrial cancer subtypes: insights from multiomics analysis

Background: Endometrial cancer (EC) as one of the most common gynecologic malignancies is increasing in incidence during the past 10 years. Genome-Wide Association Studies (GWAS) extended to metabolic and protein phenotypes inspired us to employ multiomics methods to analyze the causal relationships of plasma metabolites and proteins with EC to advance our understanding of EC biology and pave the way for more targeted approaches to its diagnosis and treatment by comparing the molecular profiles of different EC subtypes. Methods: Two-sample mendelian randomization (MR) was performed to investigate the effects of plasma metabolites and proteins on risks of different subtypes of EC (endometrioid and nonendometrioid). Pathway analysis, transcriptomic analysis, and network analysis were further employed to illustrate gene-protein-metabolites interactions underlying the pathogenesis of distinct EC histological types. Results: The authors identified 66 causal relationships between plasma metabolites and endometrioid EC, and 132 causal relationships between plasma proteins and endometrioid EC. Additionally, 40 causal relationships between plasma metabolites and nonendometrioid EC, and 125 causal relationships between plasma proteins and nonendometrioid EC were observed. Substantial differences were observed between endometrioid and nonendometrioid histological types of EC at both the metabolite and protein levels. The authors identified seven overlapping proteins (RGMA, NRXN2, EVA1C, SLC14A1, SLC6A14, SCUBE1, FGF8) in endometrioid subtype and six overlapping proteins (IL32, GRB7, L1CAM, CCL25, GGT2, PSG5) in nonendometrioid subtype and conducted network analysis of above proteins and metabolites to identify coregulated nodes. Conclusions: Our findings observed substantial differences between endometrioid and nonendometrioid EC at the metabolite and protein levels, providing novel insights into gene-protein-metabolites interactions that could influence future EC treatments.

The value of transitory protective stomas during primary debulking surgery for advanced epithelial ovarian cancer: a retrospective cohort study

Objectives: Limited data are available on patients with advanced-stage epithelial ovarian cancer (OC) who require ostomy during primary cytoreductive surgery. This study aimed to investigate the application of postoperative and long-term oncological results from transitory protective stoma (TPS) formation during primary debulking surgery for OC. Methods: This is a retrospective cohort study with a single center. The authors identified patients with stage III–IV OC who underwent colon resection and anastomosis. Depending on the methods used after colorectal anastomosis and the outcomes of surgical resection, the patients were stratified into three groups: resection and end-to-end anastomosis, resection and ostomy, or R1 resection. Demographic and clinical data were analyzed. Results: Eighty-four patients underwent colorectal resection during cytoreduction for FIGO stage III–IV OC. Patients undergoing ostomy were more likely to have a longer mean operative time (266 vs. 283 vs. 236 min; P=0.003) and to undergo rectosigmoid resection at the time of cytoreductive surgery (56.0 vs. 22.7%, P=0.007). Their postoperative feeding (7 vs. 1 vs. 3 days, P<0.001) and exhaustion (6 vs. 3 vs. 3, P<0.001) times were similar to those of patients with R1 resection and much earlier than those of patients with intestinal anastomosis. The first normal time (35 days) and half-life (14.68 days) of CA125 after surgery were significantly better in patients with TPS group. The overall incidence of complications was the same, and there was no significant difference in the 30-day readmission rate. The overall quality of life assessment was significantly lower in the R1 resection group. Conclusions: TPSs can accelerate postoperative recovery and the initiation of postoperative chemotherapy, reduce the risk of mortality and disease progression and limit the incidence of complications.

Prognosis of uterine and extrauterine low-grade endometrial stromal sarcoma: an observational cohort study

Objective: Little is known about the survival differences between uterine and extrauterine low-grade endometrial stromal sarcoma (LGESS). Survival outcomes, consisting of disease-free survivals and overall survivals (OS), were compared in these two entities. Methods: From February 2012 to June 2019, all primary LGESS cases and LGESS cases with first recurrence in the study center were reviewed. The clinicopathological characteristics and survival outcomes of extrauterine and uterine LGESS patients were compared for both primary and recurrent diseases. Results: During the study period, 143 patients with primary LGESS and 56 patients with recurrent LGESS were included and followed up to 1 June 2020, among whom 8 (5.6%) and 10 (17.8%) patients were identified as having extrauterine LGESS. Patients with primary and recurrent extrauterine LGESS had similar clinicopathological characteristics to those of patients with uterine LGESS. In primary or in recurrent LGESS cases, in univariate analysis, patients with uterine and extrauterine LGESS had similar disease-free intervals after the last treatment, and they also had similar OSs after the diagnosis. Ovarian preservation led to significantly increased recurrence for primary LGESS [hazard ratio (HR) 4.9, 95% CI: 2.3–10.1, P<0.001) and repeated recurrence for recurrent LGESS (HR 3.1, 95% CI: 1.3–7.3, P=0.009). Surgical treatment for recurrent LGESS decreased repeated recurrence after the first recurrence (HR 0.2, 95% CI: 0.1–0.7, P=0.006). No factors were found to be associated with the OS of primary or recurrent LGESS. Conclusion: The clinical characteristics and survival outcomes of extrauterine LGESS are similar to those of uterine LGESS. Surgery is the treatment of choice for recurrent LGESS. Ovarian preservation is detrimental to disease-free survival but not to OS in both uterine and extrauterine LGESS.

Comparison of different tracers in sentinel lymph node detection for endometrial cancer: a systematic review and network meta-analysis

Background: In the realm of endometrial cancer (EC) therapeutics and prognostic assessments, lymph nodes’ status is paramount. The sentinel lymph node (SLN) detection, recognized for its reliability, has been progressively adopted as a standard procedure, posing a compelling alternative to conventional systematic lymphadenectomy. However, there remains a lack of agreement on the most effective choice of tracers for this procedure. Objective: This investigation was dedicated to a comparative analysis of various tracers to identify the most effective combination that achieves the highest detection rate. This endeavor sought to enhance the efficacy of SLN biopsy in the surgical management of EC. Methods: A systematic review was conducted across multiple databases, including the Cochrane Central Register of Controlled Trials, PubMed, Web of Science, Embase, and clinicaltrials.gov, to analyze studies employing different tracers for SLN biopsy during surgery in EC. Using Bayesian network meta-analysis, the authors compared the total and bilateral detection rates of various tracers. Results: After screening 1431 articles, 11 studies, including 2699 participants, were selected in this network meta-analysis. The combination of radioactive isotopes and indocyanine green (ICG) emerged as the most efficacious method in total and bilateral detection rates, with the Surface Under the Cumulative Ranking Curve (SUCRA) scores of 80.00 and 86.36%, respectively. Additionally, carbon nanoparticles (CNPs) demonstrated superior performance in the detection of para-aortic lymph nodes with an SUCRA score of 97.77%. Conclusion: Network meta-analysis shows that the application of radioactive isotopes and ICG is the optimal tracer combination for SLN biopsy during surgery in EC.

Efficacy of vaginal natural orifice transluminal endoscopic sentinel lymph node biopsy for endometrial cancer: a prospective multicenter cohort study

Introduction: Natural orifice transluminal endoscopic surgery (NOTES) is performed increasingly often despite the lack of high-quality evidence confirming its safety, especially for malignant diseases. The aim of this prospective study is to verify that vaginal NOTES (vNOTES) can be performed safely and effectively in early endometrial cancer staging surgery. Materials and Methods: This prospective study was conducted in two tertiary hospitals in southern China from January 2021 to May 2022. A total of 120 patients with stage I endometrial cancer were included. vNOTES or multiport laparoscopic staging surgery was selected according to each patient’s wishes. The primary outcome was the sentinel lymph node detection rate, analyzed by a noninferiority test. The secondary outcomes were perioperative outcomes. Results: Among the 120 patients enrolled, 57 underwent vNOTES, and 63 underwent multiport laparoscopy. The patient-specific detection rates of sentinel lymph nodes were 94.73 and 96.82% in the vNOTES and laparoscopy groups, respectively. Additionally, the bilateral detection rates were 82.46 and 84.13%, and the side-specific detection rates were 88.60 and 90.48% in these two groups, respectively. All three detection rates in the vNOTES group were noninferior to those of laparoscopy group at a noninferiority cutoff of –15%. The median operation times of the vNOTES and laparoscopy groups were 132.35 and 138.73 min (P=0.362), and the median estimated blood loss were 75 and 50 ml (P=0.096), respectively. No intraoperative complications occurred in either group. The pain scores on the Numerical Rating Scale at both 12 h and 24 h after operation were significantly lower in the vNOTES group (P<0.001) and the median postoperative hospital stay was significantly shorter in the vNOTES group (P=0.001). Conclusion: This study illustrates the potential applicability of vNOTES in gynecological malignancy surgery by demonstrating its safety and effectiveness in endometrial cancer staging. However, its long-term survival outcomes require further exploration.

Associations of biological age accelerations and genetic risk with incident endometrial cancer: a prospective analysis in UK Biobank

Background: Endometrial cancer (EC) is one of the gynecologic malignancy cancer with increasing incidence and mortality rates, partly due to aging populations and genetic risks. This study explores the associations between biological age accelerations (BAA) and risk of incident EC and assesses the joint effect of genetic factors and BAA. Materials and methods: Based on the UK Biobank cohort, 132 315 women participants were included for primary analysis and 124 119 white participants for genetic risk analysis. Biological age (BA) was calculated using the Klemera-Doubal (KDM) and PhenoAge method based on clinical biomarkers. The authors calculated two metrics for BAA (including KDM residual and PhenoAge residual) using residual analysis, comparing them against chronological age. The risk of incident EC was evaluated using multivariable Cox proportional-hazards models, adjusting for relevant covariates. Polygenic risk scores (PRS) were computed from known EC-associated SNPs. Results: Both KDM and PhenoAge residual, were significantly associated with increased EC risk. In fully adjusted models, the highest tertile of KDM and PhenoAge residual was significantly associated with incident EC compared with the lowest group, with HRs of 1.278 ( P =0.0044) and 1.424 ( P <0.0001), repectively. The population-attributable fractions were 7.84% for KDM residual ( P =0.0044), 9.78% for PhenoAge residual ( P =0.0005), and 8.47% for genetic risk ( P =0.0005). Additionally, joint associations of BAA and genetic risk with incident EC was evaluated. Compared with low genetic risk and low BAA, high genetic risk and high BAA was significantly associated with the incidence of EC with HRs of up to 2.172 (95% CI: 1.592–2.963) for KDM and 2.226 (95% CI: 1.640–3.022) for PhenoAge. Overall, higher levels of PhenoAge residual were consistently associated with an increased risk of incident EC, regardless of genetic risk. Conclusion: BAA and genetics both enhance the risk of incident EC. The effect of the PhenoAge residual is greater than that of the investigated genes, which in turn is greater than that of the KDM residual. These findings highlight the importance of considering both BAA and genetic factors in EC prevention.

Laparoendoscopic single site myomectomy versus conventional laparoscopic myomectomy for uterine myomas: a systematic review and meta-analysis

Background: Although uterine myomas can be treated with drugs, uterine artery embolization, and high-intensity focused ultrasound, myomectomy is still the most commonly used treatment in women who wish to preserve fertility. This study aimed to assess the current evidence regarding the safety, efficiency, and potential advantages of laparoendoscopic single-site myomectomy (LESS-M) for treating uterine myomas. Materials and methods: We comprehensively searched MEDLINE, Embase, the Cochrane Library, ClinicalTrials.gov, and the World Health Organization’s International Clinical Trials Registry Platform from their inception to 16 November 2024. We included Randomized controlled trials and non-randomized studies comparing LESS-M with conventional laparoscopic myomectomy (CLM) for treating uterine myomas. The primary outcomes were perioperative complication rate, postoperative pain, and cosmetic satisfaction. The secondary outcomes included operative time (min), estimated blood loss (ml), hemoglobin drop, blood transfusion, blood transfusion, conversion to laparotomy rate, first exhaust time, postoperative ambulation time, postoperative hospital stay. All analyses were performed using random-effects or fixed-effects models. Exploration of causes of clinical heterogeneity was planned using subgroup analysis and sensitivity analysis. Results: We included 20 studies including 2766 patients in the final analysis. There were no significant differences between LESS-M and CLM in terms of perioperative complication rate (RR, 1.19; 95% CI, 0.65 to 2.18; P = 0.50), postoperative pain scores at 6 h (WMD, −0.25; 95% CI, −0.53 to 0.03; P = 0.08), 24 h (WMD, −0.16; 95% CI, −0.41 to 0.09; P = 0.22), and 48 h (WMD, −0.05; 95% CI, −0.21 to 0.12; P = 0.58). There were also no differences in terms of operative time ( P = 0.56), estimated blood loss ( P = 0.36), hemoglobin drop ( P = 0.77), blood transfusion ( P = 0.87), and first exhaust time ( P = 0.60) between both techniques. LESS-M was associated with higher cosmetic satisfaction ( P < 0.00001), reduction in postoperative pain scores at 1 h ( P = 0.0008) and 12 h ( P = 0.001), shorter postoperative ambulation time ( P = 0.02) and hospital stay ( P = 0.003) comparing with CLM. Conclusion: Available evidence suggests that LESS-M may have advantages in some short-term outcomes compared to CLM. However, these findings are primarily based on non-randomized studies, and further high-quality randomized controlled trials are needed to confirm these results.

Comparing the KangDuo Surgical Robot-01 and da Vinci Xi system for endometrial cancer surgery: a multi-center, randomized, parallel-controlled, noninferiority trial

Background: The outcomes of patients who undergo surgical staging for endometrial cancer using the KangDuo Surgical Robot-01 (KD-SR-01) have not been compared with those of patients who undergo this procedure using the da Vinci Xi system. The aim of this study is to evaluate the efficacy and safety of the KD-SR-01 system for surgical staging of endometrial cancer by comparing short-term outcomes to those of counterparts who underwent surgery using the da Vinci Xi system. Materials and methods: This multi-center, randomized, noninferiority trial was conducted at four hospitals. Overall, 99 patients aged 18–80 years with endometrial cancer were enrolled between May 2022 and June 2023. Participants were randomized to receive surgical staging using either the KD-SR-01 (KD group) or da Vinci Xi system (DV group). The primary endpoint was the surgical success rate. The secondary endpoints were the number of harvested lymph nodes and surgical satisfaction. Safety evaluation included the docking time, console time, intraoperative blood loss, and complications. The follow-up period was 6 weeks. Results: All surgeries were completed without converting to open or other laparoscopic procedures. No significant difference was noted in the number of dissected lymph nodes between the KD and DV groups (13.29 vs. 16.92, P = 0.10). Per the National Aeronautics and Space Administration task load index, significant differences were found between the groups only in performance and frustration (P < 0.05) but not in the other categories. Compared to patients in the DV group, no significant differences were observed in console time, intraoperative blood loss, or complications in the KD group (P > 0.05). Only the docking time was longer in the latter (5.39 vs. 4.34 minutes, P = 0.01). Conclusion: The clinical application of the KD-SR-01 system for endometrial cancer staging surgery is safe and effective, with short-term results comparable to those achieved with the da Vinci Xi system after sufficient training.

Comparing robotic, laparoscopic, and laparotomy in endometrial cancer: a network meta-analysis

Background: This study aims to assess the comparative effectiveness and safety of robotic-assisted surgery (RAS), laparoscopy (LPS), and laparotomy (LPT) in improving perioperative indicators, lymph node dissection, and tumor survival outcomes in patients with endometrial carcinoma (EC) through a systematic review and network meta-analysis (NMA). Materials and methods: We searched China National Knowledge Infrastructure, Wanfang, WeiPu, China Biology Medicine Disc, Embase, PubMed, Web of Science, and the Cochrane Library for randomized controlled trials (RCTs) and cohort studies (CSs) involving RAS, LPS and LPT in individuals with EC. The NMA employed a Bayesian framework to integrate direct and indirect evidence, calculating odds ratios (OR) and mean difference (MD). Markov chain Monte Carlo methods generated posterior distributions, comparing and ranking treatments using surface under the cumulative ranking (SUCRA) values. Regression and sensitivity analyses assessed the impact of different variables on the results. Results: 37 eligible trials involving 3 surgical techniques and 6,558 participants were included in this NMA. Our data showed that RAS was the most effective way for reducing estimated blood loss (MD −193; 95% CI [−279.38 to −106.95]; SUCRA 80.3%), length of hospital stay (MD −3.8; 95% CI [−5.37 to −2.31]; SUCRA 90.2%), transfusion rate (OR 0.13; 95% CI [0.06 to 0.28]; SUCRA 87%), intraoperative complications (OR 0.23; 95% CI [0.06 to 0.8]; SUCRA 91.3%), postoperative complications (OR 0.29; 95% CI [0.18 to 0.51]; SUCRA 98.8%), and total complications (OR 0.24; 95% CI [0.1 to 0.61]; SUCRA 96%). However, the analysis showed no significant differences in the dissection of lymph nodes and tumor survival outcomes. Conclusion: Our results showed that RAS was the most effective surgical method for improving perioperative indicators in EC. If hospital resources are limited, LPS is a suitable alternative. Further research is needed to confirm these findings and ensure that the benefits of minimally invasive surgeries extend to long-term survival outcomes.

The incidence of perioperative lymphatic complications after radical hysterectomy and pelvic lymphadenectomy between robotic and laparoscopic approach : a systemic review and meta-analysis

Background: Although many studies have reported perioperative complications after radical hysterectomy and pelvic lymph node dissection using robotic and laparoscopic approaches, the risk of perioperative lymphatic complications has not been well identified. The aim of this meta-analysis is to compare the risks of perioperative lymphatic complications after robotic radical hysterectomy and lymph node dissection (RRHND) with laparoscopic radical hysterectomy and lymph node dissection (LRHND) for early uterine cervical cancer. Materials and Methods: The authors searched the PubMed, Cochrane Library, Web of Science, ScienceDirect, and Google Scholar databases for studies published up to July 2022 comparing perioperative lymphatic complications after RRHND and LRHND while treating early uterine cervical cancer. Related articles and bibliographies of relevant studies were also checked. Two reviewers independently performed the data extraction. Results: A total of 19 eligible clinical trials (15 retrospective studies and 4 prospective studies) comprising 3079 patients were included in this analysis. Only 107 patients (3.48%) had perioperative lymphatic complications, of which the most common was lymphedema (n=57, 1.85%), followed by symptomatic lymphocele (n=30, 0.97%), and lymphorrhea (n=15, 0.49%). When all studies were pooled, the odds ratio for the risk of any lymphatic complication after RRHND compared with LRHND was 1.27 (95% CI: 0.86–1.89; P=0.230). In the subgroup analysis, study quality, country of research, and publication year were not associated with perioperative lymphatic complications. Conclusions: A meta-analysis of the available current literature suggests that RRHND is not superior to LRHND in terms of perioperative lymphatic complications.

Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials

Background: Glucagon-like peptide-1 receptor (GLP1R) agonists have been approved by Food and Drug Administration for management of obesity. However, the causal relationship of GLP1R agonists (GLP1RA) with cancers still unclear. Methods: The available cis-eQTLs for drugs target genes (GLP1R) were used as proxies for exposure to GLP1RA. Mendelian randomizations (MR) were performed to reveal the association of genetically-proxied GLP1RA with 14 common types cancer from large-scale consortia. Type 2 diabetes was used as positive control, and the GWASs data including 80 154 cases and 853 816 controls. Replicating the findings in the FinnGen study and then pooled with meta-analysis. Finally, all the related randomized controlled trails (RCTs) on GLP1RA were systematically searched from PubMed, Embase, and the Cochrane Library to comprehensively synthesize the evidence to validate any possible association with cancers. Result: A total of 22 significant cis-eQTL single-nucleotide polymorphisms were included as genetic instrument. The association of genetically-proxied GLP1RA with significantly decreased type 2 diabetes risk [OR (95%)=0.82 (0.79–0.86), P<0.001], which ensuring the effectiveness of identified genetic instruments. The authors found favorable evidence to support the association of GLP1RA with reduced breast cancer and basal cell carcinoma risk [0.92 (0.88–0.96), P<0.001, 0.92 (0.85–0.99), P=0.029, respectively], and with increased colorectal cancer risk [1.12 (1.07–1.18), P<0.001]. In addition, there was no suggestive evidence to support the association of GLP1RA with ovarian cancer [0.99 (0.90–1.09), P=0.827], lung cancer [1.01 (0.93–1.10), P=0760], and thyroid cancer [0.83 (0.63–1.10), P=0.187]. Our findings were consistent with the meta-analysis. Finally, 80 RCTs were included in the systematic review, with a low incidence of different kinds of cancer. Conclusions: Our study suggests that GLP1RA may decrease the risk of breast cancer and basal cell carcinoma, but increase the risk of colorectal cancer. However, according to the systematic review of RCTs, the incidence of cancer in patients treated with GLP1RA is low. Larger sample sizes of RCTs with long-term follow-up are necessary to establish the incidence of cancers and evaluate the risk-benefit ratios.

Global trends, risk factors, and future projections of ovarian cancer burden among women aged 50 years and older: a systematic analysis based on GBD 2021

Background: Ovarian cancer (OC) remains one of the most lethal gynecological malignancies worldwide, with a disproportionate burden in older women. This study aims to quantify and project the OC burden from 1990 to 2021 using data from the Global Burden of Disease Study 2021 (GBD 2021). Methods: Leveraging data from the GBD 2021, this study comprehensively assessed trends in OC-related disability-adjusted life years (DALYs), deaths, incidence, and prevalence across 204 countries and 21 regions from 1990 to 2021, and age-standardized rates were calculated. Joinpoint regression and age-period-cohort (APC) modeling were used to identify temporal trends and cohort effects. Inequality was assessed using the Slope Index of Inequality (SII) and Concentration Index (CI). The Bayesian age-period-cohort (BAPC) model was applied to project OC burden through 2050. Results: From 1990 to 2021, absolute DALYs, deaths, incidence, and prevalence of OC among women ≥50 years increased markedly, while ASRs declined globally. High and high-middle SDI regions exhibited the highest burden, particularly among women under 75 years. Australasia demonstrated sustained improvement, whereas Andean Latin America experienced worsening trends. Health inequality, reflected in declining SII and CI values, has narrowed since 1990. High BMI emerged as the dominant risk factor, especially in Central Europe. Occupational asbestos exposure remained regionally significant, particularly in Australasia. Projections indicate continued increases in OC burden through 2050, driven by demographic aging and rising life expectancy. Conclusion: Despite improvements in age-standardized OC metrics, the absolute burden continues to rise globally, underscoring the need for age- and region-specific strategies.

Risk factors for anastomotic leakage and its impact on survival outcomes in radical multivisceral surgery for advanced ovarian cancer: an AGO-OVAR.OP3/LION exploratory analysis

Background: Anastomotic leakage is a significant complication following bowel resection in cytoreductive surgery for ovarian cancer. Previous studies have highlighted the detrimental effects of anastomotic leakage on patients’ postoperative course. However, there is still a lack of precise identification of the high-risk population and established strategies for preventing its occurrence. Materials and methods: Patients who underwent bowel resection within the surgical phase III trial AGO-OVAR.OP3/LION investigating the impact of systematic pelvic and paraaortic lymphadenectomy in cytoreductive surgery for primary ovarian cancer were included in this analysis. All patients in the AGO-OVAR.OP3/LION trial had undergone complete cytoreduction with no macroscopic residual disease. We analyzed the occurrence of anastomotic leakage regarding surgical procedure (non-lymphadenectomy vs. lymphadenectomy and non-stoma vs. stoma) using the Fisher test. Risk factors for anastomotic leakage and its prognostic impact on survival were analyzed. Results: Overall rate of anastomotic leakage was 7.1%. Notably, the Non-lymphadenectomy subgroup had a lower anastomotic leakage rate of 3.0% compared to the lymphadenectomy subgroup (11.2%, P = 0.005). The use of protective stoma placement resulted in an anastomotic leakage rate of 5.5% regardless of lymphadenectomy compared to the Non-Stoma subgroup (7.5%, P = 0.78). Increased blood loss (odds ratio [OR] 1.04 per 100cc, 95% confidence interval [CI] 1.0001–1.09) and lymphadenectomy (OR 3.67, 95% CI 1.41–11.40) were associated with a higher risk of anastomotic leakage. Although anastomotic leakage demonstrated a numerical detrimental impact on median progression-free survival (PFS) (18 months with anastomotic leakage vs. 19 months with Non-anastomotic leakage, hazard ratio [HR] 0.86; 95% CI 0.5 to 1.4, P = 0.53) and median overall survival (OS) (31 months with anastomotic leakage vs. 58 months with Non-anastomotic leakage, HR 0.69; 95% CI 0.4 to 1.2, P = 0.17), the differences were not statistically significant. Conclusion: Anastomotic leakage rates were lower in the Non-lymphadenectomy arm, the current standard of care. Blood loss and lymphadenectomy, as surrogate markers for extensive surgery, were associated with increased risk for anastomotic leakage. These findings highlight the importance of strategies to reduce surgical complexity and perioperative risk to improve clinical outcomes.

Incidence, prevalence, deaths, and DALYs of diseases of the female reproductive system from 1990 to 2021 across 204 countries: data, with critical re-analysis, from the global burden of disease study

Background: Female reproductive system diseases severely threaten women’s health. This study aims to evaluate the disease burden caused by female reproductive system diseases from 1990 to 2021. Methods: We extracted female reproductive system disorder data from the Global Burden of Disease Study 2021. First, we assessed the global and subtype-specific incidence, prevalence, deaths, and disability-adjusted life years (DALYs) in 2021, reported as absolute numbers and age-standardized rates (ASIR, ASPR, ASDR, and AS-DALYs). Temporal trends from 1990 to 2021 were analyzed using linear regression models, with estimated annual percentage change quantifying burden trajectories. Finally, Bayesian hierarchical models were applied to project future disease burden. Results: In 2021, global gynecological disease burdens showed distinct patterns. Cervical cancer: 667 426 incident cases (ASIR 7.79) and 296 667 deaths (ASDR 3.44); ovarian cancer: 298 876 cases (ASIR 3.48) with 185 609 deaths (ASDR 2.16); uterine cancer: 473 614 cases (ASIR 5.41) resulting in 97 672 deaths (ASDR 1.14); uterine fibroids: prevalence dominated with 10.1 million cases (ASIR 124.22) but minimal mortality (2078 deaths; ASDR 0.02); female infertility: affected 110.1 million women with 601 134 DALYs. Temporal analysis (1990–2021) revealed rising absolute case numbers alongside stable/declining ASRs for cervical and ovarian cancers. Disease burden peaked in middle-aged and older populations. Different diseases present distinct patterns of geographical distribution. Projections through 2045 forecast continued case count increases for malignancies and fibroids, with ASRs remaining stable for cervical cancer and infertility. Conclusion: This study offers a comprehensive and updated evaluation of the global burden of female reproductive system diseases. The findings underscore the pressing need for targeted interventions and policies to address these conditions.

The role of immune cell signatures in the pathogenesis of ovarian-related diseases: a causal inference based on Mendelian randomization

Background: Immune cells play a pivotal role in maintaining ovarian function. However, the specific contributions of different immune cell phenotypes to the pathogenesis of specific ovarian-related diseases remain poorly understood. The authors aim to investigate the correlation between 731 immunophenotypes and ovarian-related diseases. Materials and methods: Utilizing publicly available genetic data, the authors undertook a series of quality control measures to identify instrumental variables associated with exposure. Subsequently, we conducted two-sample Mendelian randomization (MR) using inverse variance weighting to explore the causal relationships between 731 immune cell features and six ovarian-related diseases: ovarian cysts, ovarian dysfunction, premature ovarian failure (POF), polycystic ovary syndrome (PCOS), benign neoplasm of ovary, and malignant neoplasm of ovary at the genetic level. Sensitivity analyses, including leave-one-out and other MR analysis models, were performed. Finally, Bayesian colocalization (COLOC) analysis was employed to identify specific co-localized genes, thereby validating the MR results. Results: At the significance level corrected by Bonferroni, four immune phenotypes, including CD25 on IgD- CD38- B cells, were associated with ovarian cysts; four immune phenotypes, including CD39+ CD4+ T cell Absolute Count, were associated with ovarian dysfunction; eight immune phenotypes, including SSC-A on HLA DR+ CD8+ T cells, were associated with POF; five immune phenotypes, including CD20- CD38- B cell Absolute Count, were associated with PCOS; five immune phenotypes, including CD4+ CD8dim T cell Absolute Count, were associated with benign ovarian tumors; and three immune phenotypes, including BAFF-R on IgD- CD38+ B cells, were associated with malignant ovarian tumors. Sensitivity analysis indicated robust results. COLOC analysis identified four immune cell co-localized variants (rs150386792, rs117936291, rs75926368, and rs575687159) with ovarian diseases. Conclusion: Our study elucidates the close genetic associations between immune cells and six ovarian-related diseases, thereby providing valuable insights for future research endeavors and clinical applications.

Global, regional, and national burden of ovarian cancer, 1990–2021, and projections to 2050: a cross-sectional analysis of the Global Burden of Disease Study 2021

Background: Ovarian cancer remains the most lethal gynecological cancer, with fewer than 50% of patients surviving more than 5 years after diagnosis. This study aimed to analyze the global epidemiological trends of ovarian cancer from 1990 to 2021 and also project its prevalence to 2050, providing insights into these evolving patterns and helping health policymakers use healthcare resources more effectively. Methods: This study comprehensively analyzes the original data related to ovarian cancer from the Global Burden of Disease Study 2021 database, employing a variety of methods including descriptive analysis, correlation analysis, age–period–cohort analysis, decomposition analysis, predictive analysis, frontier analysis, and health inequality analysis. The aim is to explore the disease burden of ovarian cancer and its changing trends in detail. Results: From 1990 to 2021, the age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and age-standardized disability-adjusted life year rate (ASDR) for ovarian cancer significantly increased, while the age-standardized prevalence rate (ASPR) showed a marked decline. In 2021, the ASIR of ovarian cancer was 6.71 per 100 000 population, the ASPR was 28.08 per 100 000, the ASMR was 4.06 per 100 000, and the ASDR was 115.15 per 100 000. As the Social Development Index (SDI) increased, the disease burden of ovarian cancer exhibited a trend of rising initially followed by a decline. Health inequalities between countries have slowed, but high-SDI countries remain the primary regions with the greatest disease burden. The age-standardized rates (ASRs) of ovarian cancer increased with age, with population growth being a major driver of the rise in ovarian cancer ASRs. Furthermore, the effects of aging and epidemiological changes vary across different regions. Predictive results indicate that from 2022 to 2050, both the ASIR and ASPR for ovarian cancer will continue to rise, while the ASMR and ASDR will initially decrease before increasing again. High body mass index and occupational exposure to asbestos are the primary risk factors contributing to ovarian cancer. Conclusions: Although the disease burden of ovarian cancer showed a downward trend from 1990 to 2021, a potential rebound may occur in the future. The disease burden of ovarian cancer exhibits significant heterogeneity across age, time, and geographical regions. Greater attention to these factors is needed moving forward.

A multi-modal model integrating MRI habitat and clinicopathology to predict platinum sensitivity in patients with high-grade serous ovarian cancer: a diagnostic study

Background: Platinum resistance of high-grade serous ovarian cancer (HGSOC) cannot currently be recognized by specific molecular biomarkers. We aimed to compare the predictive capacity of various models integrating MRI habitat, whole slide images (WSIs), and clinical parameters to predict platinum sensitivity in HGSOC patients. Methods: A retrospective study involving 998 eligible patients from four hospitals was conducted. MRI habitats were clustered using K-means algorithm on multi-parametric MRI. Following feature extraction and selection, a Habitat model was developed. Vision Transformer (ViT) and multi-instance learning were trained to derive the patch-level prediction and WSI-level prediction on hematoxylin and eosin (H&E)-stained WSIs, respectively, forming a Pathology model. Logistic regression (LR) was used to create a Clinic model. A multi-modal model integrating Clinic, Habitat, and Pathology (CHP) was constructed using Multi-Head Attention (MHA) and compared with the unimodal models and Ensemble multi-modal models. The area under the curve (AUC) and integrated discrimination improvement (IDI) value were used to assess model performance and gains. Results: In the internal validation cohort and the external test cohort, the Habitat model showed the highest AUCs (0.722 and 0.685) compared to the Clinic model (0.683 and 0.681) and the Pathology model (0.533 and 0.565), respectively. The AUCs (0.789 and 0.807) of the multi-modal model interating CHP based on MHA were highest than those of any unimodal models and Ensemble multi-modal models, with positive IDI values. Conclusion: MRI-based habitat imaging showed potentials to predict platinum sensitivity in HGSOC patients. Multi-modal integration of CHP based on MHA was helpful to improve prediction performance.

Phenylephrine-induced blood pressure elevation reduces pulmonary edema and distention fluid absorption in hysteroscopic myomectomy: a randomized controlled trial

Background: Hysteroscopic myomectomy is a common procedure for treating submucosal leiomyomas, but fluid overload and subsequent pulmonary edema are significant complications. This study investigates whether phenylephrine-induced increases in mean arterial pressure (MAP) can reduce pulmonary edema and distention fluid absorption in patients undergoing hysteroscopic myomectomy. Material and Methods: This randomized controlled trial enrolled 44 patients scheduled for hysteroscopic myomectomy. Patients were randomly assigned to receive either phenylephrine infusion to maintain MAP at 100–120% of the baseline value or normal saline infusion during surgery. The primary outcome was the incidence of pulmonary edema assessed by lung ultrasound (LUS). Secondary outcomes included B-line scores, thoracic fluid content (TFC), distention fluid deficit, use of furosemide, and so on. Receiver operating characteristic (ROC) curve analysis was performed in distention fluid deficit and ΔTFC to predict pulmonary edema. Results: The phenylephrine group showed a significantly lower incidence of pulmonary edema [18.2 vs. 54.6%, RR = 0.33, 95% CI (0.13–0.81), P = 0.027] and lower LUS B-line scores [MD = −4.5, 95% CI (0–9), P = 0.016] compared to the control group. Additionally, the phenylephrine group had significantly reduced distention fluid deficit ( P = 0.018), lower TFC at the end of operation ( P = 0.008), and decreased use of furosemide ( P = 0.022). The best cutoff value in the diagnosis of pulmonary edema was 1900 ml for distention fluid deficit and 7.1/kΩ for ΔTFC, and areas under the ROC curves were 0.85, and 0.83, respectively. Conclusion: Phenylephrine administration during hysteroscopic myomectomy effectively reduces pulmonary edema and distention fluid absorption by increasing MAP. This study provides evidence for a new strategy in intraoperative fluid management for hysteroscopic surgeries.

Low anterior resection syndrome (LARS) in ovarian cancer patients - A multi-centre comparative cohort study

Low anterior resection syndrome (LARS) is a common functional disorder after low anterior resection impacting the quality of life. Data on LARS derives nearly exclusively from rectal cancer studies. Therefore, the study was designed to assess LARS in advanced epithelial ovarian cancer (EOC) patients, who underwent rectal resection and to compare it with a female rectal cancer cohort. A cross-sectional multi-centre analysis was performed on female patients suffering from either rectal or EOC who received a low anterior resection as part of their therapy regimen. None of the patients received pre- or postoperative radiotherapy. LARS was defined by using the validated LARS score and its severity was divided into "no", "minor" and "major LARS". In total, 125 female patients (44.8% (n = 56) EOC vs. 55.2% (n = 69) rectal cancer patients) met the final inclusion criteria and were retrospectively analyzed. Baseline characteristics were comparable between the groups. Median follow-up was 22 (IQR 12-56) months. In total, 30.4% (n = 38) of the patient group reported bowel dysfunction after surgery. Rates of LARS were not significantly different between EOC and rectal cancer patients (major LARS 16.1% (n = 9) vs. 15.9% (n = 11); minor LARS 17.9% (n = 10) vs. 11.6% (n = 8); p = 0.984). The time interval between surgery and final assessment had no impact on the postoperative bowel function (p = 0.820). LARS is a frequent and highly underreported postoperative disorder in EOC patients who require cytoreductive surgery with rectal resection. The functional outcome is comparable to female patients with rectal cancer who underwent low anterior resection without receiving radiotherapy.

Laparoscopic management of isolated nodal recurrence in gynecological malignancies is safe and feasible even for large metastatic nodes up to 8 cm: A prospective case series

The surgical treatment of isolated lymph node recurrence (ILNR) of gynecological malignancies is still debated. The feasibility and effectiveness of minimally invasive lymphadenectomy have been reported by few studies; however, it remains unclear what the upper tumor size limit is for a minimally invasive approach. We prospectively analyzed cases of ILNR treated by laparoscopy in our unit while focusing on the safety and feasibility of resecting large tumors suspected of recurrence using a minimally invasive approach. We carried out a prospective observational case-series study. We included all consecutive patients with ILNR from gynecological cancers who underwent minimally invasive lymphadenectomy at our unit from June 2013 to June 2021 to assess the safety and feasibility of such a surgical approach. We also evaluated the oncological outcome in terms of further recurrence, site of recurrence, and survival. Twenty-seven patients with ILNR due to gynecological malignancies were included (ovarian cancer, 12; uterine malignancies, 12; cervical cancer, 3). Three had remarkably large LNs up to 8 cm: these emblematic cases have been reported in detail with accompanying videos of the surgical procedure. The most frequent site of ILNR was aortic (67%). Recurrent LNs were completely resected in all cases; none of the procedures was converted to open surgery. The median follow-up duration was 24 months. Ten patients (37%) had a new recurrence. To date five patients (18.5%) have succumbed, four (14.8%) are alive with evidence of disease, and 18 (66.7%) are alive with no evidence of disease. Minimally invasive surgery for ILNR in gynecological malignancies may be an option feasible, safe, and effective in terms of oncological outcomes, even for large tumors. It also allows quicker recovery with early initiation of appropriate postoperative systemic chemotherapy, in the context of an optimal multimodal therapeutic approach.

AI-powered pathobiology transformers predict prognosis and targeted therapy benefits in patients with colorectal cancer ovarian metastases: a multicohort study

Background: Individualized postoperative management of colorectal ovarian metastases demands precision medicine tools, yet current approaches lack consideration of prognostic heterogeneity and targeted therapy benefit guidance and suffer from high costs and long turnaround times of genetic testing. Methods: In this retrospective, prospective multicohort study, we developed and validated an interpretable transformer-based transfer learning model to predict patient prognosis, targeted therapy benefits, and molecular mutations by integrating digital pathology with RNA data. The performance of the model was assessed with the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, specificity, positive predictive value, and negative predictive value. Results: The model accurately predicted peritoneal recurrence, with AUCs of 0.90, 0.74, and 0.83 across patient cohorts. It also achieved precise prognostic stratification for peritoneal recurrence-free survival in the training [hazard ratio (HR) = 107.22, 95% confidence interval (CI) 24.18 – 475.52; P < 0.001], external test (HR = 4.97, 95% CI 1.16 – 21.37; P = 0.03), and prospective test (HR = 10.53, 95% CI 2.02 – 54.94; P = 0.01) sets. The model revealed a significant association between prognostic stratification and tumor microenvironment heterogeneity ( P < 0.05), thereby enhancing its biological interpretability. Further analysis revealed that only patients classified as high risk with BRAF/RAS mutations could benefit from the addition of targeted therapy to adjuvant chemotherapy (HR 0.38, 95% CI 0.18 – 0.79; P = 0.007). Moreover, the model predicted BRAF/RAS mutations with AUCs of 0.96/0.94 in the training set, maintaining cross-cohort generalizability with AUCs of 0.64 – 0.83. Conclusions: This pathobiology-based deep learning model can robustly detect prognosis and mutation and identify targeted therapy beneficiaries, serving as a potential precision tool in clinical decision making for the management of colorectal ovarian metastases.

Causal impact of obesity class stratification and endometrial cancer subtypes: an integrated Mendelian randomization and Global Burden of Disease Study 2021 analysis

Background: An elevated body mass index (BMI) is recognized as a significant risk factor for uterine cancer. This is especially true for endometrial cancer, which accounts for over 90% of uterine cancer cases. However, establishing a causal relationship and accurately measuring its impact on a population scale requires comprehensive epidemiological validation. Methods: We investigated the influence of increased BMI (≥25 kg/m 2 ) on the burden of uterine cancer by utilizing the Global Burden of Disease (GBD) 2021 data covering the period from 1990 to 2021, with a particular emphasis on mortality and disability-adjusted life years (DALYs). Age-standardized morbidity rates were evaluated to compute the estimated annual percentage change (EAPC) through linear regression analyses. Demographic decomposition techniques were employed to analyze the contributions of population growth, aging, and the accumulation of risk factors. A comparison of national performance was made against sociodemographically-adjusted theoretical minimum risk levels using frontier analysis. Additionally, Bayesian age-period-cohort (BAPC) modeling was utilized to project trends in disease burden through 2036. To establish causality between obesity classifications (BMI 30–34.9, 35–39.9, and ≥40 kg/m 2 ) and the subtypes of endometrial cancer (endometrioid versus non-endometrioid), we performed a two-sample Mendelian randomization (MR) analysis with multivariable adjustments, leveraging data from IEU OpenGWAS. The analysis was further fortified by inverse variance-weighted (IVW) methods and pleiotropy-resistant MR strategies, complemented by sensitivity assessments to verify robustness. Results: The GBD analysis revealed a consistent global rise in the burden of uterine cancer attributable to elevated BMI (≥25 kg/m 2 ) over the last three decades. Age-standardized DALYs rates (ASDR) and mortality rates (ASMR) exhibited a strong correlation with the Socio-Demographic Index (SDI). The morbidity was notably highest among individuals aged 60–74 years, who accounted for the largest number of deaths and DALYs, while those aged ≥90 years had the highest age-specific mortality rates. The burden was most pronounced in high-income regions of North America and areas with elevated SDI. Projections suggested an increase in global mortality, DALYs, age-standardized mortality rates (ASMR), and disability-adjusted rates (ASDR) across all age demographics through 2036 in the absence of targeted preventative measures. The multivariable-adjusted MR analysis validated a dose-dependent causal link, indicating that Class I obesity (BMI 30–34.9 kg/m 2 ) was associated with a 27% heightened risk of endometrioid carcinoma (95% CI 1.19–1.36; P < 0.001), which is below the existing screening thresholds. A gradual increase in risk for endometrioid cancer was identified across obesity Classes I–III, independent of confounding variables, while no association was found for non-endometrioid subtypes. The results’ robustness was affirmed through IVW and pleiotropy-resistant MR methodologies. Conclusions: An elevated body mass index (BMI) is a modifiable causal factor for uterine cancer, especially endometrial cancer. This type of cancer disproportionately affects older populations and regions with high socio-demographic indices (SDI). Findings from Mendelian randomization (MR) and the Global Burden of Disease (GBD) highlight the urgent need for targeted obesity interventions to reduce disease burden in vulnerable populations.

Publisher

Ovid Technologies (Wolters Kluwer Health)

ISSN

1743-9159